Radionecrosis after stereotactic radiotherapy for brain metastases

Archive ouverte

Le Rhun, E. | Dhermain, F. | Vogin, G. | Reyns, N. | Metellus, P.

Edité par CCSD ; Taylor & Francis -

International audience. Introduction: Radionecrosis (RN) represents the main complication of stereotactic radiotherapy (SRT) for brain metastases. It may be observed in up to 34% of cases at 24 months after treatment and associated with significant morbidity in 10-17%.Areas covered: Our aim is to discuss the results of original studies on RN related to SRT for brain metastases. Expert commentary: Although the development of RN is unpredictable, larger volume of the lesion, prior whole brain irradiation, and higher dose of radiation represent the major risk factors. RN appears on MRI as contrast-enhancing necrotic lesions, surrounded by edema, occurring at least 3 months after SRT, localized within fields of irradiation. No firm criteria are established. Surgery can provide symptomatic relief but is associated with a risk of complications. Corticosteroids are considered the standard of care treatment, despite limited efficacy and many adverse effects. Bevacizumab represents another interesting option that needs to be validated.

Consulter en ligne

Suggestions

Du même auteur

Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era

Archive ouverte | Remon, J. | CCSD

International audience. Leptomeningeal metastasis is a fatal manifestation seen in advanced cancer patients. Its incidence is increasing, reaching 3.8% in molecularly unselected non-small cell lung cancer patients a...

Systemic therapy for recurrent meningioma

Archive ouverte | Le Rhun, E. | CCSD

International audience. Introduction: Meningioma comprise 20-30% of all primary brain tumors. Notwithstanding surgery and radiotherapy, a subset of patients will manifest recurrent meningioma. Systemic therapy is re...

Combined irradiation and targeted therapy or immune checkpoint blockade in brain metastases: toxicities and efficacy

Archive ouverte | Tallet, A.V. | CCSD

International audience. Background: Targeted therapies (TT) and immune checkpoint inhibitors (ICI) are currently modifying the landscape of metastatic cancer management and are increasingly used over the course of m...

Chargement des enrichissements...